The latest update is out from MaxCyte ( (MXCT) ).
MaxCyte, Inc. announced the vesting of restricted stock units (RSUs) to its Chief Financial Officer, Douglas Swirsky, resulting in the issuance of 20,313 new shares of Common Stock. To cover withholding tax liabilities, 6,939 of these shares were automatically sold, representing 2.2% of Mr. Swirsky’s total equity and option holdings. This transaction reflects routine financial management and does not indicate a change in Mr. Swirsky’s investment strategy. The announcement underscores MaxCyte’s ongoing commitment to compliance and transparency in its financial operations.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell-engineering industry, specializing in platform technologies that facilitate the discovery, development, and commercialization of next-generation cell-based therapeutics. The company’s ExPERT™ platform, which utilizes Flow Electroporation® technology, supports the rapidly growing cell therapy market, offering a range of instruments, processing assemblies, and software protocols. MaxCyte aims to transform human health by providing partners with advanced technology and comprehensive support.
YTD Price Performance: -25.93%
Average Trading Volume: 39,949
Technical Sentiment Signal: Strong Buy
Current Market Cap: £258M
For an in-depth examination of MXCT stock, go to TipRanks’ Stock Analysis page.